Abstract:We have shown that the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide (Lir) inhibits development of early atherosclerosis in vivo by modulating immune cell function. We hypothesized that Lir could attenuate pre-established disease by modulating monocyte or macrophage phenotype to induce atheroprotective responses. Human atherosclerotic plaques obtained postendarterectomy and human peripheral blood macrophages were treated ex vivo with Lir. In parallel, apolipoprotein E–deficient (ApoE–/–) mice received a high-fat, high-cholesterol diet to induce atherosclerosis for 8 weeks, after which ApoE–/– mice received 300 μg/kg of Lir daily or vehicle control for a further 4 weeks to investigate the attenuation of atherosclerosis. Lir inhibited proinflammatory monocyte chemoattractant protein-1 secretion from human endarterectomy samples and monocyte chemoattractant protein-1, tumor necrosis factor-α, and interleukin (IL)-1β secretion from human macrophages after ex vivo treatment. An increase in CD206 mRNA and IL-10 secretion was also detected, which implies resolution of inflammation. Importantly, Lir significantly attenuated pre-established atherosclerosis in ApoE–/– mice in the whole aorta and aortic root. Proteomic analysis of ApoE–/– bone marrow cells showed that Lir upregulated the proinflammatory cathepsin protein family, which was abolished in differentiated macrophages. In addition, flow cytometry analysis of bone marrow cells induced a shift toward reduced proinflammatory and increased anti-inflammatory macrophages. We concluded that Lir attenuates pre-established atherosclerosis in vivo by altering proinflammatory mediators. This is the first study to describe a mechanism through which Lir attenuates atherosclerosis by increasing bone marrow proinflammatory protein expression, which is lost in differentiated bone marrow–derived macrophages. This study contributes to our understanding of the anti-inflammatory and cardioprotective role of GLP-1RAs.SIGNIFICANCE STATEMENTIt is critical to understand the mechanisms through which liraglutide (Lir) mediates a cardioprotective effect as many type 2 diabetic medications increase the risk of myocardial infarction and stroke. We have identified that Lir reduces proinflammatory immune cell populations and mediators from plaque-burdened murine aortas in vivo and augments proresolving bone marrow–derived macrophages in attenuation of atherosclerotic disease, which provides further insight into the atheroprotective effect of Lir.

Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes

Lixisenatide Attenuates Advanced Glycation End Products (Ages)-Induced Degradation of Extracellular Matrix in Human Primary Chondrocytes

Glucagon-Like Peptide-1 Analogue Liraglutide Ameliorates Atherogenesis Via Inhibiting Advanced Glycation End Product-Induced Receptor for Advanced Glycosylation End Product Expression in Apolipoprotein-E Deficient Mice

The GLP-1 Agonist, Liraglutide, Ameliorates Inflammation Through the Activation of the PKA/CREB Pathway in a Rat Model of Knee Osteoarthritis

The Role of PPARγ in Advanced Glycation End Products-Induced Inflammatory Response in Human Chondrocytes.

Anti-arthritic effects of chlorogenic acid in interleukin-1β-induced rabbit chondrocytes and a rabbit osteoarthritis model.

Inhibiting Receptor for Advanced Glycation End Product (age) and Oxidative Stress Involved in the Protective Effect Mediated by Glucagon-Like Peptide-1 Receptor on Age Induced Neuronal Apoptosis

Pioglitazone inhibits advanced glycation end product-induced TNF-α and MMP-13 expression via the antagonism of NF-κB activation in chondrocytes.

Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro

Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis

Sitagliptin Ameliorates Advanced Glycation End-Product (Age)-Induced Degradation of Extracellular Matrix in Human Primary Chondrocytes.

The Effect Of Liraglutide On The Proliferation, Migration, And Osteogenic Differentiation Of Human Periodontal Ligament Cells

Liraglutide Alleviates Arteriosclerotic Lesions and Inhibits Receptor for Advanced Glycation End-Product Expression in Diabetic ApoE-/- Mice

The Function Of Ppar Gamma/Ampk/Sirt-1 Pathway In Inflammatory Response Of Human Articular Chondrocytes Stimulated By Advanced Glycation End Products

Liraglutide Prevents High Glucose Induced HUVECs Dysfunction Via Inhibition of PINK1/Parkin-dependent Mitophagy

Effects of GLP-1 Receptor Analogue Liraglutide and DPP-4 Inhibitor Vildagliptin on the Bone Metabolism in ApoE(-/-) Mice

Liraglutide regulates bone destruction and exhibits anti-inflammatory effects in periodontitis <i>in vitro</i> and <i>in vivo</i>

Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E–Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators

Trelagliptin ameliorates IL-1β-impaired chondrocyte function via the AMPK/SOX-9 pathway

Liraglutide attenuates palmitate-induced apoptosis via PKA/β-catenin/Bcl-2/Bax pathway in MC3T3-E1 cells

Agonism of GPR39 displays protective effects against advanced glycation end-product (AGE)-induced degradation of extracellular matrix in human SW1353 cells